Pharmaceutical Technology

NOVEMBER 21, 2022

However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). The MHLW is currently proposing discussions on the FY2023 drug price revision.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 52

European Pharmaceutical Review

NOVEMBER 8, 2022

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 5) monitoring access to biosimilars.

Biosimilars 52

Biosimilars Drug Pricing Pharmaceutical Manufacturing Pharmaceutical Companies 52

Proxsys Rx

JANUARY 10, 2023

Nobody’s ever put it better than the Association of American Medical Colleges (AAMC): “Congress created the 340B Drug Pricing Program in 1992 to protect safety-net hospitals from escalating drug prices by allowing them to purchase outpatient drugs at a discount from manufacturers. percent to 3.5

Hospitals 52

Hospitals Drug Pricing Pharmaceutical Manufacturing Pharmaceutical Companies 52

FDA Law Blog: Biosimilars

APRIL 16, 2024

Vanda Pharmaceuticals, Inc. Under the Medicaid Drug Rebate statute, a pharmaceutical manufacturer whose drug prices increase faster than the rate of inflation must pay additional per-unit rebates to the program. Centers for Medicare and Medicaid Servs., 23-1457 (4th Cir.

Dosage 59

Dosage Drug Pricing Pharmaceutical Manufacturing 59

Proxsys Rx

OCTOBER 6, 2022

That’s why helping health systems minimize data mismatches at the source is so critical to maximizing 340B savings 340B drug pricing program savings for a covered entity — and why meeting that challenge is a core component of our 340B software and service package. And that reason has to be defensible, if it’s challenged in audit.

Hospitals 52

Hospitals Drug Pricing Communication Pharmaceutical Manufacturing 52

Putting Patients First Blog

MAY 6, 2025

4 ,5 Millions of Americans rely on medicines that are manufactured outside the United States, particularly from close and longstanding allies such as Ireland, Switzerland, and the United Kingdomcountries whose regulatory frameworks for pharmaceutical manufacturing mirror the high standards enforced domestically. Hanna et al.,

Pharmaceutical Manufacturing 52

Pharmaceutical Manufacturing Generic Medicine Drug Pricing Hospitals 52

FDA Law Blog: Biosimilars

MAY 13, 2025

Wasserstein We are still parsing through the May 12 Executive Order (EO), Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients and impacts this may have on the pharmaceutical industry. The May 12 EO regarding personal importation is similar in this regard to the EO from 2020. Please bear with us.)

Online Pharmacies 59

Online Pharmacies Drug Pricing Documentation Pharmaceutical Manufacturing 59

FDA Law Blog: Biosimilars

MAY 12, 2025

Kirschenbaum On September 15, 2020, I posted an article in this blog entitled Trump Embraces International Reference Pricing in Executive Order, which described an order in Trumps first administration to use most-favored-nation (MFN) pricing as a limit on Medicare payment. Within 30 days (i.e., and other developed countries.

Department of Veterans Affairs 64

Department of Veterans Affairs Drug Pricing Pharmaceutical Manufacturing Biosimilars 64

FDA Law Blog: Biosimilars

MAY 21, 2025

Kirschenbaum Following up on Donald Trumps May 12 Executive Order on Most Favored Nation Prescription Drug Pricing (see our post here ), The Department of Health and Human Services today issued a brief press release answering two of the multitude of questions raised by the Executive Order. GDP per capita. According to the U.S.

Biosimilars 59

Biosimilars Communication Drug Pricing Pharmaceutical Manufacturing 59